News

11. April 2023

AMW Reports Financial Results 2022 and Provides Corporate Update

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today reported financial results for the year ended December 31, 2022. AMW posted a 2022 consolidated record revenue of EUR 22,8 million and achieved operating profitability for the first time in the Company’s history. The Company also announced that Philipp Karbach will take over as Chief Executive Officer (CEO) from June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH, effective May 31, 2023, to pursue new opportunities. Philipp Karbach has been with the Company since 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).

7. February 2023

AMW Appoints Prof. Dr. Olivia Merkel to its Scientific Advisory Board

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor for Drug Delivery in the Department of Pharmacy at Ludwig-Maximilians-Universität (LMU) Munich, Germany, as a member to AMW’s Scientific Advisory Board (SAB). Prof. Merkel is an internationally renowned expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will further broaden AMW’s scientific expertise in sustained-release systems, such as biodegradable implants, and contribute to the Company’s strategic development plans. With her appointment, Prof. Merkel will succeed Prof. Dr. Gerhard Winter, who will step down from his position on the SAB.

9. January 2023

AMW and SAJA Pharmaceuticals sign License and Supply Agreement for Commercialization of AMW’s Goserelin Implant

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and SAJA Pharmaceuticals, a leading regional pharmaceutical manufacturer based in Jeddah, Saudi Arabia, with a presence throughout the MENA region, today announced that they have entered into an exclusive license and supply agreement for the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.

22. December 2022

Additional Market Authorizations within the EU for AMW’s Leuprorelin Implant for the Treatment of Hormone-Dependent Tumors

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that its leuprorelin implant has received market authorization in two EU countries. Leuprorelin enables symptomatic therapy of hormone-dependent tumors, such as prostate cancer, as well as certain gynecological disorders. AMW’s leuprorelin implant is now approved in more than 10 countries worldwide as a cost-effective therapy.

25. October 2022

AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.

10. August 2022

AMW Strengthens Management Team to Support the Company’s Growth Strategy

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.